{"title":"Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview.","authors":"Sourav Thakur, Bhupendra Singh, Vijay Mishra, Nishika Yadav, Namita Giri, Pardeep Sharma, Ankit Saini, Lavi K Garg","doi":"10.2174/1872211313666190227204127","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Asthma is a common ailment with a larger circadian difference. Nocturnal Asthma (NA) is an inconstant exacerbation of asthmatic condition related to the rise in warning sign during the night time and there is a need for its treatment addressing air route alertness and decline in lung functions. These symptoms are linked to sleep or known as circadian events. Chronotherapeutics is a management system based on an in-vivo drug accessibility programmed to check the rhythms of ailment in a direction to improve the therapeutic outcomes by suppressing the side effects. This review aims to provide an overview of NA, chronotherapeutics for the treatment of NA, bilayer tablets, and advanced techniques involved in the fabrication of bilayer tablets. The review also discusses some of the related patents.</p><p><strong>Methods: </strong>Relevant literature about the latest developments and updated information related to NA, chronotherapeutics and bilayer tablets has been very widely searched on different biomedical literature programs such as Google, Web of Science, PubMed portals, etc. Bilayer tablet mediated chronotherapy has gained significant attention and consideration as it is developed and fabricated based on the body's circadian rhythm. Bilayer tablets can deliver the bioactive compounds at an appropriate time, place as well as amount and site.</p><p><strong>Results: </strong>Available literature advocated that the bilayer matrix tablet containing a single drug in the sustained release film and fast releasing film, may be beneficial for the chronic diseases like asthma, migraine, diabetes, hypertension and inflammation which usually require immediate as well as maintained therapeutic effect.</p><p><strong>Conclusion: </strong>The application of nanotechnology in the arena of medicine will transform the diagnosis and treatment strategies of a wide range of diseases in the upcoming years. The findings of this review confirm the importance of bilayer tablet based chronotherapy in nocturnal asthma.</p>","PeriodicalId":40024,"journal":{"name":"Recent Patents on Drug Delivery and Formulation","volume":"13 2","pages":"74-82"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Patents on Drug Delivery and Formulation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872211313666190227204127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 5
Abstract
Background: Asthma is a common ailment with a larger circadian difference. Nocturnal Asthma (NA) is an inconstant exacerbation of asthmatic condition related to the rise in warning sign during the night time and there is a need for its treatment addressing air route alertness and decline in lung functions. These symptoms are linked to sleep or known as circadian events. Chronotherapeutics is a management system based on an in-vivo drug accessibility programmed to check the rhythms of ailment in a direction to improve the therapeutic outcomes by suppressing the side effects. This review aims to provide an overview of NA, chronotherapeutics for the treatment of NA, bilayer tablets, and advanced techniques involved in the fabrication of bilayer tablets. The review also discusses some of the related patents.
Methods: Relevant literature about the latest developments and updated information related to NA, chronotherapeutics and bilayer tablets has been very widely searched on different biomedical literature programs such as Google, Web of Science, PubMed portals, etc. Bilayer tablet mediated chronotherapy has gained significant attention and consideration as it is developed and fabricated based on the body's circadian rhythm. Bilayer tablets can deliver the bioactive compounds at an appropriate time, place as well as amount and site.
Results: Available literature advocated that the bilayer matrix tablet containing a single drug in the sustained release film and fast releasing film, may be beneficial for the chronic diseases like asthma, migraine, diabetes, hypertension and inflammation which usually require immediate as well as maintained therapeutic effect.
Conclusion: The application of nanotechnology in the arena of medicine will transform the diagnosis and treatment strategies of a wide range of diseases in the upcoming years. The findings of this review confirm the importance of bilayer tablet based chronotherapy in nocturnal asthma.
背景:哮喘是一种具有较大昼夜差异的常见疾病。夜间哮喘(NA)是一种与夜间警告信号升高有关的哮喘病情的不稳定加重，需要对其进行治疗，以解决气道警觉性和肺功能下降的问题。这些症状与睡眠有关，或被称为昼夜节律事件。时间疗法是一种基于体内药物可及性的管理系统，旨在通过抑制副作用来检查疾病的节律，从而改善治疗效果。本文综述了NA、NA治疗的时间疗法、双分子层片剂以及制备双分子层片剂的先进技术。本文还对相关专利进行了讨论。方法:在Google、Web of Science、PubMed等不同的生物医学文献网站上广泛检索NA、时间疗法和双层片的最新进展和更新信息。双层片剂介导的时间疗法由于是基于人体的昼夜节律而开发和制造的，因此受到了极大的关注和考虑。双层片剂可以在适当的时间、地点、剂量和部位给药。结果:现有文献认为，在缓释膜和快速释放膜中含有单一药物的双层基质片，可能对哮喘、偏头痛、糖尿病、高血压、炎症等慢性疾病具有立竿见影的疗效。结论:纳米技术在医学领域的应用将在未来几年改变多种疾病的诊断和治疗策略。本综述的结果证实了以双分子层片为基础的时间疗法在夜间哮喘中的重要性。
期刊介绍：
Recent Patents on Drug Delivery & Formulation publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents on drug delivery and formulation. A selection of important and recent patents on drug delivery and formulation is also included in the journal. The journal is essential reading for all researchers involved in the fields of drug delivery and formulation. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to drug delivery and formulations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
